Navigation Links
Arena Pharmaceuticals Announces Public Offering of Common Stock
Date:10/19/2007

SAN DIEGO, Oct. 19 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has filed a preliminary prospectus supplement to a shelf registration statement with the Securities and Exchange Commission relating to a proposed public offering of 10,000,000 shares of its common stock. In connection with this offering, Arena plans to grant to the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any. All of the shares are being offered by Arena. CIBC World Markets and UBS Investment Bank are acting as joint book-running managers in this offering.

The securities may not be sold nor may offers to buy be accepted prior to the time that a final prospectus supplement is filed with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Copies of the preliminary prospectus may be obtained from CIBC World Markets by email at useprospectus@us.cibc.com, by phone at 212.667.7200, by fax at 212.667.6303, or by mail at CIBC World Markets, Attn: USE Prospectus Department, 425 Lexington Avenue, 5th floor, New York, NY 10017, or from UBS Investment Bank, Prospectus Department, 299 Park Avenue, 8th floor, New York, NY 10171 or by phone at 888.827.7275.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682

http://www.arenapharm.com


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
(Date:4/28/2017)... ... 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... to and which He does not. Yisrayl says with so many titles and names ... name, but he says with a little Scripture, backed with a lot of research, the ...
(Date:4/28/2017)... ... 28, 2017 , ... Intellitec Solutions announced the publication of ... Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software package. With ... care, Brooke Grove now has the capability to achieve its goal for a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor ... leant his presence to an educational purpose as the host of the “Informed” series. ... cancer. In a recent episode, the series focuses on thyroid cancer. , Although thyroid ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology: